To assess the effect of EZH2 inhibition on H3K27me3 levels, we treated HepG2 HCC cells with tazemetostat, a selective EZH2 inhibitor, or performed EZH2 knockdown. This evidence concerns the gene EZH2 and hepatocellular carcinoma.